Fig. 6
From: Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity
Hornerin knockdown in combination with VEGFR inhibition (AV-951) resulted in an enhanced reduction in tumor burden compared to monotherapy. a Timeline showing points of treatment over the course of the 15-day experiment. On day 5, control and 1.0 mg/kg AV-951-treated tumors were randomly selected to receive either Scr or Hrnr siRNA, resulting in four treatment groups. b Tumor volume (N = 8 tumors/treatment group) on day 5 post implantation in control and AV-951-treated mice. c Tumor volume was again calculated at day 14 post implantation. N = 4 in each treatment group, except control (N = 3). See Methods section for explanation of outlier exclusion. d Representative whole-mounted Z-stacked images of CD34+ vessels from each treatment group. e The number of CD34+ vessels per 0.4 mm2 field was quantified in 20 representative 5 μm sections (four tumors in each treatment group, five images per tumor). Images from 12 whole-mounted Z-stacks (50 μm sections) from each group (three fields per tumor, four tumors in each group) were analyzed by RAVE for f radius distribution and g vessel volume fraction. h Ratiometric quantification, determined by dividing ACTA2-positive pixels by CD34-positive pixels, of 12 images from each group (four tumors per group, three sections per tumor). Scale bar = 100 μm. Graphs represent mean ± SEM. *P < 0.05, **P < 0.005 by unpaired two-tailed t-test compared to control group
